Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human
males over the age of 50 which increases in prevalence with age and 40% of males reported
moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this
study is to collect safety and efficacy data for this dosage regimen of cetrorelix pamoate.
For this study, study medication (Cetrorelix pamoate) is administered by injection in the
buttocks (Intramuscular).